The problem for many biotechs is that they are a one trick pony. It hardly seems the case with AdAlta although at the moment the fog over a phase 2 deal for AD-214 shrouds everything else. Eventually the fog will lift and when it does investors will see the incredible potential inside the collaborative deal with SYNthesis BioVentures.
It does two things. Firstly, arguably its a validation of AD-214 and the i-body drug discovery platform. Secondly, its a conduit for innovative science in cellular immunotherapies evolving in the Asian region and in particular China, for entry into the western regulatory system and ultimately western markets - the east to west cellular immunotherapy strategy.
What are we to make of it? I could suggest that research might start with the article in The Australian What’s next for the man who landed big pharma’s billions, dated 17 May 2024. Spoiler alert, it doesn't mention AdCella but it will acquaint you with Professor Andrew Wilks.
